Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
This predictive technology empowers people with diabetes to take preventive action before complications arise
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
Bayer Co.Lab AdVenture platform will accelerate biotech innovation through global investment networks
Subscribe To Our Newsletter & Stay Updated
